Albatroz Therapeutics Pte Ltd. has secured $3 million in seed funding to develop therapeutic antibodies against a new target that degrades the extracellular matrix, a key contributor to cancer and arthritis.

Meio Medical Inc.’s Titian, a surgical robot for navigation in cardiac electrophysiology, has been included in a Green Pathway for approval of medical devices in China, meaning it could get to market faster. Inclusion in the Green Pathway gives the medical device priority for reviewing and shortens the average registration time. Currently, Meio Medical is running a trial of Titian in multiple hospitals in China.

Qritive Pte. Ltd. launched Qai Prostate, an artificial intelligence (AI)-powered diagnostic tool, to help pathologists detect prostate cancer.

Beijing Surgerii Technology Co. Ltd. completed a series C3 round to support the development of its robotic system for single-port laparoscopic surgery.

Tessara Therapeutics Pty Ltd. is developing a technology platform that builds three-dimensional models of the human brain to treat neurological diseases such as Parkinson’s disease.

Sometimes the simplest solution is the most elegant solution, and that is certainly the case for Livac Pty Ltd.’s minimally invasive liver vacuum retractor device known as the Livac.

Biontech SE has tapped into two of Duality Biologics Co. Ltd.’s antibody-drug conjugate candidates (ADCs), paying Duality $170 million up front and agreeing on development, regulatory and commercial milestone fees of $1.5 billion or more.